1.Experimental section
General chemistry:All reagents were commercial and were used without further purification.
Chromatography was carried on silica gel (60-120 and 100-200 mesh). All reactions were monitored by thin-layer chromatography (TLC), silica gel plates with fluorescence F254 were used. Melting points were taken in open capillaries on Complab melting point apparatus and are presented uncorrected. 1 H NMR and 13 C NMR spectra were recorded using BrukerSupercon Magnet DRX spectrometer (operating at 300 and 400 MHz for 1 H and 50, 75, 100 MHz for 13 C) using CDCl 3, DMSO-d 6 as solvent and tetramethylsilane (TMS) as an internal standard. Chemical shifts are reported in parts per million. Electrospray ionization mass spectra (ESIMS) were recorded on Thermo Lcq Advantage Max-IT. High-resolution mass spectra (HRMS) were recorded on 6520 Agilent Q TofLC-MS/MS (Accurate mass). Elemental analyses were performed on a Vario EL-III C, H, N, S analyzer (Germany) and Carlo-Erba-1108 C, H, N elemental analyzer (Italian), and values were within ±0.5% of the calculated values; therefore, these compounds meet the criteria of > 95% purity. A purity of ≥ 95% has been established for compounds, which showed good in vivo activity.
Representative procedure compounds (8a-8p):Solution of 4a or 4b (1 eq.) 1, 2 amine (1.2 eq.) and isocyanide (1.2 eq.) was stirred in anhydrous methanol (5mL) at RT for 10 min. Thereafter, sodium azide (3 eq.) was added and the resulting mixture was further stirred for 6h. On completion of the reaction (checked by TLC analysis), the methanol was removed in vacuo. The crude product was subjected to silica gel column chromatography using chloroform/methanol as the mobile phase to afford the desired compounds. [3,4-b] [3,4-b] [3,4- [3,4- Cytotoxicity assay: The toxicity of synthesized compounds was tested on RCOs. Cells were cultured in the absence or presence of compounds at various concentrations (1 pM to1μM) for 48h. The cell viability was determined by using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. 5
Charterization of compounds: methyl 1-((benzylamino)(1-(tert-butyl)-1H-tetrazol-5-yl)methyl)-9H-pyrido

Methyl1-((1-tert-butyl-1H-tetrazol-5-yl)(4-methylbenzylamino)methyl)-9H-pyrido
ethyl1-((1-tert-butyl-1H-tetrazol-5-yl)(morpholino)methyl)-9H-pyrido[3,4-b]indole-3-carboxylate
(8k) -solid,
ethyl1-((4-(benzo
[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)(1-tert-butyl-1H-tetrazol-5-yl)methyl)- 9H-pyrido[3,4-b]indole-3-carboxylate (8l) -solid,
ethyl1-((1-tert-butyl-1H-tetrazol-5-yl)(4-(furan-2-carbonyl)piperazin-1-yl)methyl)-9H-pyrido
methyl1-((1-tert-butyl-1H-tetrazol-5-yl)(2-methoxy-2-oxoethylamino)methyl)-9H-pyrido
RNA isolation and Real-Time Polymerase Chain Reaction (RT-PCR):
At the endof the treatment, RCOs were homogenized using 1mlof TRIzol reagent (Invitrogen), and total RNA was extracted according to themanufacturer's protocol. For bone-specific gene expression analysis,frozen femur bones were crushed in liquid nitrogen and homogenized using 1ml of TRIzol reagent (Invitrogen), followed by total RNA extraction using manufacturer's protocol. Primers were designed using the Universal Probe Library (Roche Applied Sciences) for the selected genes and given in Table S2 (supporting information). 3 Representative images of transverse sections (5.0μm) of livers followed by hematoxylin and eosin staining after 12 weeks of treatment to the rats.Vehicle represents 1% gum acacia dissolved in distilled water.
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